<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23406736</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>02</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
                <ISOAbbreviation>Ann Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1491-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mds654</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This phase 2 study enrolled breast cancer patients with stage 3 and stage 4 without evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin &lt;17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty patients (28 stage 2/3, 12 stage 4 NED) were
                    enrolled. Seventy-five percent patients achieved the copper depletion target by 1 month. Ninety-one
                    percent of triple-negative patients copper-depleted compared with 41% luminal subtypes. In
                    copper-depleted patients only, there was a significant reduction in EPCs/ml by 27 (P = 0.04). Six
                    patients relapsed while on study, of which only one patient had EPCs maintained below comparison.
                    The 10-month relapse-free survival was 85.0% (95% CI 74.6%-96.8%). Only grade 3/4 toxicity was
                    hematologic: neutropenia (3.1% of cycles), febrile neutropenia (0.2%), and anemia (0.2%).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TM is safe and appears to maintain EPCs below baseline in copper-depleted patients. TM may promote tumor dormancy and ultimately prevent relapse.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ward</LastName>
                    <ForeName>M M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kornhauser</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chuang</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cigler</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moore</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donovan</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lam</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cobham</LastName>
                    <ForeName>M V</ForeName>
                    <Initials>MV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schneider</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hurtado RÃºa</LastName>
                    <ForeName>S M</ForeName>
                    <Initials>SM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Benkert</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mathijsen Greenwood</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zelkowitz</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Warren</LastName>
                    <ForeName>J D</ForeName>
                    <Initials>JD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lane</LastName>
                    <ForeName>M E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mittal</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rafii</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vahdat</LastName>
                    <ForeName>L T</ForeName>
                    <Initials>LT</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>UL1 TR000457</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1-RR024996</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>02</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002614">Chelating Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>789U1901C5</RegistryNumber>
                <NameOfSubstance UI="D003300">Copper</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>81AH48963U</RegistryNumber>
                <NameOfSubstance UI="D008982">Molybdenum</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>91U3TGV99T</RegistryNumber>
                <NameOfSubstance UI="C020809">tetrathiomolybdate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002614" MajorTopicYN="N">Chelating Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008982" MajorTopicYN="N">Molybdenum</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">endothelial progenitor cells</Keyword>
            <Keyword MajorTopicYN="N">tetrathiomolybdate</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23406736</ArticleId>
            <ArticleId IdType="pii">S0923-7534(19)37288-6</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mds654</ArticleId>
            <ArticleId IdType="pmc">PMC3707432</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1989 Nov;86(21):8427-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2813401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2002 Mar;2(3):161-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11990853</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1991 Jan 3;324(1):1-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1701519</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Neurol. 1991 Jan;48(1):42-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1986725</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gene Ther. 2002 May;9(10):631-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12032709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2002 Sep 1;62(17):4854-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12208730</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2003 May;9(5):1666-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12738719</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2009 Aug;1796(1):33-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19460418</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Oct 1;69(19):7875-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19789345</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Dec 1;15(23):7441-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19934283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2010 Jan 15;327(5963):331-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19965379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Jul 1;29(19):2619-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21606424</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Jul 1;29(19):2628-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21606433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 Aug 1;71(15):5090-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21653680</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 26;366(4):299-309</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22276820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Feb;132(1):235-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22160642</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011;13(5):R97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21978456</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 1995 Jan;1(1):27-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7584949</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Thromb Haemost. 1997 Jul;78(1):672-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9198237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2005;7(4):R402-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15987445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Dec 8;438(7069):820-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16341007</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2006 Apr 27;440(7088):1222-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16642001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Aug 15;12(16):4974-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16914587</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):299-310</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16924372</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2247-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17283338</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2007 Mar;6(3):1039-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17363496</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2007 Dec 27;357(26):2666-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18160686</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2008 Jan 11;319(5860):195-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18187653</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2008 Feb 26;98(4):776-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18253124</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Thorac Surg. 2008 Aug;86(2):383-9; discussion 390</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18640301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2009 Jan 6;15(1):35-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19111879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Invest New Drugs. 2009 Apr;27(2):159-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18712502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2009 Apr;9(4):239-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19279573</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2000 Jan;6(1):1-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10656425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann N Y Acad Sci. 2001 Jun;938:36-45; discussion 45-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11458524</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 1990 Nov;137(5):1121-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1700617</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
